Trials / Completed
CompletedNCT01998984
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 266 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2 trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily treatment for 2, 3 or 4 consecutive days compared to vehicle gel
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ingenol mebutate | |
| OTHER | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2013-12-03
- Last updated
- 2025-03-10
- Results posted
- 2018-12-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01998984. Inclusion in this directory is not an endorsement.